BLOOD

Scope & Guideline

Transforming Insights into Blood Science.

Introduction

Welcome to the BLOOD information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of BLOOD, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0006-4971
PublisherAMER SOC HEMATOLOGY
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1946 to 2024
AbbreviationBLOOD / Blood
Frequency52 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2021 L ST NW, SUITE 900, WASHINGTON, DC 20036

Aims and Scopes

The journal 'BLOOD' focuses on advancing the field of hematology through innovative research that encompasses various aspects of blood disorders, including their biology, diagnosis, treatment, and patient management.
  1. Hematologic Malignancies:
    A core focus of the journal is on hematologic cancers such as leukemia, lymphoma, and myeloma, including studies on their molecular mechanisms, therapeutic strategies, and clinical outcomes.
  2. Transfusion Medicine and Hemostasis:
    Research related to blood transfusion practices, coagulation disorders, and the management of bleeding disorders is prominently featured, emphasizing both clinical and laboratory aspects.
  3. Genomics and Precision Medicine:
    The journal publishes studies on the genetic basis of blood disorders and the application of genomic technologies to personalize treatment approaches.
  4. Immunotherapy and Novel Therapeutics:
    There is a significant focus on immunotherapeutic strategies, including CAR T-cell therapies and monoclonal antibodies, aimed at treating various hematologic malignancies.
  5. Patient-Centered Care and Quality of Life:
    Research addressing the psychosocial aspects of hematologic diseases, including patient-reported outcomes and the impact of treatment on quality of life, is increasingly emphasized.
  6. Clinical Trials and Real-World Evidence:
    The journal highlights findings from clinical trials as well as real-world studies that provide insights into treatment effectiveness and safety in diverse populations.
The journal 'BLOOD' has witnessed a notable evolution in its scope, with emerging themes reflecting the latest advancements in hematologic research and clinical practice. These trends highlight the journal's commitment to addressing contemporary challenges in hematology.
  1. CAR T-Cell Therapy:
    There is a significant increase in research related to CAR T-cell therapies, including their development, efficacy, and management of associated toxicities, reflecting the growing importance of this treatment modality in hematologic malignancies.
  2. Genetic and Molecular Profiling:
    Studies focusing on genetic mutations, epigenetic changes, and their implications for disease progression and treatment response are becoming increasingly prevalent, emphasizing the role of precision medicine in hematology.
  3. Real-World Evidence and Health Economics:
    The journal is increasingly publishing articles that analyze real-world data to evaluate treatment outcomes and healthcare costs, highlighting the importance of pragmatic approaches in clinical decision-making.
  4. Immunotherapy Combinations:
    Emerging research on combining immunotherapies with other treatment modalities, such as targeted therapies and traditional chemotherapy, is gaining momentum, indicating a shift towards multi-faceted treatment strategies.
  5. Patient-Centered Research:
    An emphasis on patient-reported outcomes, quality of life assessments, and studies addressing the psychosocial aspects of hematologic diseases is becoming more pronounced, reflecting a holistic approach to patient care.

Declining or Waning

While the journal 'BLOOD' continues to explore a wide array of topics within hematology, certain areas have seen a decrease in focus or publication frequency over the years, reflecting evolving research priorities and advancements in the field.
  1. Traditional Chemotherapy Approaches:
    There is a declining emphasis on classical chemotherapy regimens for hematologic malignancies as newer targeted therapies and immunotherapies gain prominence.
  2. Basic Hematology Research:
    Research focused solely on basic hematology without immediate clinical application appears to be waning, as the journal increasingly prioritizes translational and clinical studies.
  3. Epidemiological Studies:
    While still relevant, the volume of purely epidemiological studies on blood disorders has decreased, with a shift towards more integrated approaches that combine clinical outcomes with genomic and molecular data.
  4. Single-Agent Therapy Studies:
    The focus on studies evaluating the efficacy of single-agent therapies has diminished, as combination therapies are recognized for their enhanced effectiveness in treating complex hematologic conditions.
  5. Niche Hematologic Disorders:
    Research on less common hematologic conditions may be receiving less attention in favor of more prevalent disorders and broader therapeutic strategies.

Similar Journals

CURRENT OPINION IN HEMATOLOGY

Exploring the forefront of hematology research and insights.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1065-6251Frequency: 6 issues/year

CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.

HemaSphere

Championing open access to vital hematology research.
Publisher: WILEYISSN: Frequency: 12 issues/year

HemaSphere, published by WILEY, stands at the forefront of hematology research, offering a vital platform for the dissemination of cutting-edge findings in the field. Since its inception in 2017 and official transition to Open Access in 2018, the journal has positioned itself as a leading conduit for high-impact research, maintaining a prestigious Q1 quartile ranking in the Hematology category as of 2023. Addressed in the United States at 111 River St, Hoboken, NJ, HemaSphere aims to foster a global dialogue among researchers, clinicians, and students by providing unrestricted access to high-quality content that encompasses clinical and experimental advancements. With an array of engaging articles, reviews, and commentaries, HemaSphere contributes significantly to the advancement of hematology, ensuring that critical knowledge is readily accessible to enhance patient care and innovative research. To explore the latest developments and breakthroughs in this dynamic field, we invite scholars, professionals, and students to engage with HemaSphere and elevate their understanding of hematologic science.

EUROPEAN JOURNAL OF HAEMATOLOGY

Transforming Hematology Through Rigorous Research
Publisher: WILEYISSN: 0902-4441Frequency: 12 issues/year

EUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.

Blood Cancer Discovery

Pioneering Discoveries for a Cancer-Free Tomorrow
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2643-3230Frequency: 6 issues/year

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

AMERICAN JOURNAL OF HEMATOLOGY

Advancing Hematological Science Through Rigorous Research
Publisher: WILEYISSN: 0361-8609Frequency: 12 issues/year

American Journal of Hematology, published by Wiley, stands as a premier outlet for the dissemination of cutting-edge research in the field of hematology. With a commendable impact factor and ranked #9 out of 137 in the Scopus medicine category, this journal has established a robust presence since its inception in 1976. Operating in the Q1 quartile for hematology, it serves as a crucial resource for researchers, clinicians, and students dedicated to understanding blood disorders and advancing treatment methodologies. While the journal does not currently offer open access options, it remains highly regarded for its rigorous peer-review process and impactful contributions to the scientific community. With coverage extending into 2024, the American Journal of Hematology is committed to fostering innovation and collaboration within the hematological sciences.

Hematology-American Society of Hematology Education Program

Empowering Knowledge in Blood Disorders
Publisher: AMER SOC HEMATOLOGYISSN: 1520-4391Frequency: 1 issue/year

Hematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.

Hematology

Innovative Insights: Shaping the Future of Hematology
Publisher: TAYLOR & FRANCIS LTDISSN: 1024-5332Frequency: 1 issue/year

Hematology is a distinguished open-access journal published by Taylor & Francis Ltd, dedicated to advancing research and knowledge in the field of hematology. Established in 1996, the journal has continually evolved to meet the needs of a growing community of researchers and practitioners, providing a vital platform for disseminating innovative findings and clinical insights. With its impact factor reflecting a robust commitment to quality scholarship, Hematology has achieved a respectable position in its category as evidenced by its Q3 ranking in the Hematology category and ranks #85 out of 137 in the Scopus index, which positions it in the 38th percentile among its peers. The journal’s open-access policy, initiated in 2019, further enhances its reach and accessibility, allowing a broad audience of professionals, researchers, and students to engage with high-quality research without barriers. By covering a wide range of topics related to blood disorders, treatment methodologies, and emerging therapies, Hematology stands as an essential resource for those dedicated to innovation in this critical area of healthcare.

Blood Transfusion

Enhancing Lives Through Blood Transfusion Innovations.
Publisher: SIMTIPRO SRLISSN: 1723-2007Frequency: 6 issues/year

Blood Transfusion is a leading journal in the fields of Hematology, Immunology, and Medicine, published by SIMTIPRO SRL in Italy. With its ISSN 1723-2007, the journal has established a significant presence in the academic community, as evidenced by its positioning within the Q2 category in Hematology and Medicine (miscellaneous) and Q3 in Immunology and Allergy for 2023. Notably, it ranks #38 out of 137 in the Hematology category, showcasing its impactful contributions to research and practice. Operating under a traditional publishing model, this journal provides valuable insights into advances in blood transfusion science, ultimately aimed at enhancing patient care and outcomes. Spanning from 2003 to 2024, the scope of Blood Transfusion covers a wide range of topics related to hematological and immunological research, making it an essential resource for researchers, healthcare professionals, and students engaged in these critical fields.

TRANSFUSION MEDICINE AND HEMOTHERAPY

Pioneering discoveries in transfusion medicine since 1973.
Publisher: KARGERISSN: 1660-3796Frequency: 6 issues/year

TRANSFUSION MEDICINE AND HEMOTHERAPY, published by KARGER, is a prominent journal dedicated to advancing the fields of hematology and transfusion medicine. With an ISSN of 1660-3796 and E-ISSN 1660-3818, this esteemed journal has been a valuable resource for researchers and clinicians since its inception in 1973, with significant publication phases continuing into 2024. It currently holds a Q2 ranking in Hematology and a Q3 ranking in Immunology and Allergy, reflecting its impact and relevance in these critical fields. The journal features original articles, reviews, and clinical studies, presenting cutting-edge research that aids in the development of effective therapies and enhances patient care. Open access options are available, ensuring that crucial findings are accessible to a broad audience. As an important platform for dialogue and advancement in transfusion science, TRANSFUSION MEDICINE AND HEMOTHERAPY supports the global health community's efforts to improve treatment outcomes and foster innovation in medical practices.

INTERNATIONAL JOURNAL OF HEMATOLOGY

Delivering Cutting-Edge Findings in Hematology
Publisher: SPRINGER JAPAN KKISSN: 0925-5710Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.